免疫检查点抑制剂是否应仅用于生物标志物筛选的儿童脑肿瘤?
该系统综述基于PRISMA指南检索截至2025年9月17日的文献,最终纳入40项研究,评估PD-1/PD-L1或CTLA-4抑制剂在≤21岁原发性中枢神经系统肿瘤患者中的疗效与毒性。在生物标志物未选择的弥漫中线胶质瘤、高级别胶质瘤、髓母细胞瘤和室管膜瘤中,客观缓解率普遍≤6%,中位无进展生存期仅1-3个月,总生存与历史对照相似;而在错配修复缺陷(MMR)或超突变队列中,PD-1阻断可产生持久缓解,约2年总生存接近50%。
要点
- 生物标志物未选择的儿童脑肿瘤中,ICI客观缓解率低(≤6%),中位PFS仅1-3个月。
- RRD/超突变肿瘤中PD-1阻断可见持久缓解,约2年OS接近50%。
- 未来试验应基于生物标志物驱动,并联合放疗、表观遗传调节剂等将「冷」肿瘤转化为可应答。
核心结论
- ICI在未选择的儿童CNS肿瘤中安全性可控但疗效有限。
- 持久获益主要体现在RRD/超突变生物学亚型及可能的PD-L1高表达 niches(如部分低级别胶质瘤和CNS-GCT)。
研究设计与样本
- PRISMA指导的系统综述,检索PubMed/MEDLINE、Embase和Scopus自建库至2025年9月17日的英文文献。
- 纳入≤21岁原发性CNS肿瘤患者接受PD-1/PD-L1或CTLA-4抑制剂治疗的研究。
- 共筛选386篇独特文献,127篇全文审查,最终40篇纳入定性合成。
主要发现
- 生物标志物未选择的弥漫中线胶质瘤、高级别胶质瘤、髓母细胞瘤和室管膜瘤中,客观缓解率普遍≤6%,中位PFS 1-3个月,OS与历史对照相似。
- 抗PD-1±抗CTLA-4治疗中,≥3级治疗相关不良事件发生率约15-25%。
- 在胚系MMR缺陷及更广泛的RRD/超突变队列中,PD-1阻断产生有临床意义且有时持久的缓解,包括恶性胶质瘤完全缓解,约2年OS接近50%,常伴延迟反应和假性进展。
- 儿童胶质瘤可分为免疫「热」、「改变」和「冷」亚型;髓母细胞瘤多PD-L1低表达,伴显著B7-H3和髓系程序;生殖细胞肿瘤和部分鞍区肿瘤也可见检查点表达。
关键数值与推荐
- 生物标志物未选择的儿童脑肿瘤中,ICI客观缓解率一般≤6%,中位PFS 1-3个月。
- RRD/超突变队列中,PD-1阻断后约2年OS接近50%。
临床怎么用
- 不应在未筛选的儿童脑肿瘤中常规使用ICI,应优先检测MMR/RRD/超突变或PD-L1等生物标志物。
- 对于RRD/超突变或PD-L1高表达肿瘤,可考虑PD-1阻断并监测延迟反应和假性进展。
- 未来临床试验应富集生物标志物阳性人群,并探索ICI联合放疗、表观遗传调节剂或节拍化疗等策略。
局限性
- 证据质量受限于样本量小、异质性大、以非对照设计为主。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Pediatric brain tumors, including high-grade gliomas (HHG), medulloblastomas (MB), and ependymomas (EPN), are a leading cause of death in children. They are often immunologically "cold" with low tumor mutational burden (TMB) and very few tumor-infiltrating lymphocytes (TILs), which may limit the role of immune checkpoint inhibitors (ICI). METHODS: We performed a PRISMA‑guided systematic review of PubMed/MEDLINE, Embase, and Scopus from inception to September 17, 2025, for English-language studies of patients ≤ 21 years with primary CNS tumors treated with PD‑1/PD‑L1 or CTLA‑4 inhibitors. Eligible reports included prospective trials, retrospective series, and observational/case reports with extractable data on efficacy and/or toxicity. Of 479 records identified, 386 unique citations were screened, 127 underwent full‑text review, and 40 met inclusion criteria for qualitative synthesis. RESULTS: Prospective and institutional studies in biomarker-unselected diffuse midline glioma, high-grade glioma, medulloblastoma, and ependymoma showed low objective response rates (generally ≤ 6%), short median progression-free survival (1-3 months), and overall survival similar to historical controls, despite acceptable safety (grade ≥ 3 treatment-related adverse events ~ 15-25% with anti-PD-1 ± anti-CTLA-4). In contrast, across germline MMR-deficient and broader RRD/hypermutant cohorts, PD-1 blockade produced clinically meaningful and sometimes durable responses, including complete remissions in malignant glioma and approximate 2-year overall survival near 50%, often with delayed responses and pseudoprogression. Histology-specific profiling highlighted marked variation in immune contexture: pediatric gliomas segregate into immune "hot," "altered," and "cold" subtypes; medulloblastoma is largely PD-L1-low with prominent B7-H3 and myeloid programs; checkpoint expression is also observed in germ cell and selected sellar tumors. Evidence quality is limited by small, heterogeneous, predominantly non-comparative designs. CONCLUSION: ICIs show manageable safety but limited efficacy in unselected pediatric CNS tumors. Durable benefit is most evident in RRD/hypermutant biology and possibly PD-L1-high niches (e.g., some low-grade gliomas and CNS-GCT). Future trials should be biomarker-driven and pair ICIs with priming combinations (e.g., radiation, epigenetic modulators, metronomic chemotherapy) to convert "cold" tumors into responders.
引用
- Levin-Carrion Y, Bhasin J, Titkov K, et al. Should checkpoint inhibitors be reserved for biomarker-selected pediatric brain tumors? J Neurooncol. 2026. PMID: 42142195. doi:10.1007/s11060-026-05605-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。